RxDoctor Payments Data

Paul Bierman, MD

Gastroenterology · Harvey, ILNPI 1144245234

Payments from drug & device makers

$21,928in general payments, 2019–2025

Across 475 payments — averaging $46.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$14K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Gilead$569
  • Takeda Pharmaceuticals U.S.A., Inc.$569
  • Olympus America Inc.$362
  • Sanofi$360
  • plus $3K from 30 others

What the payments were for

  • Speaking & faculty fees$13,80063%
  • Food & beverage$8,12037%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,928 in reported general payments places this provider in the 85th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$260,796
Medicare patients
1,044
Services billed
2,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide138$118,485
RinvoqUpadacitinib13$83,829
XifaxanRifaximin20$71,859
CreonLipase/Protease/Amylase27$48,121
ZenpepLipase/Protease/Amylase17$27,318
ViberziEluxadoline14$20,338
MovantikNaloxegol Oxalate21$15,655
Lubiprostone69$12,576
Mesalamine36$10,732
Alosetron Hcl11$9,692
Dexlansoprazole DrDexlansoprazole20$6,632
Sucralfate122$6,607
Ursodiol13$4,819
Colestipol Hcl53$4,688
Famotidine60$4,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Rinvoq, Creon, Viberzi$13,764$270,772192 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,365$71,85920 claims
Aimmune Therapeutics, Inc.Zenpep$131$27,31817 claims
Redhill Biopharma Inc.Movantik$14$15,65521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Harvey

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →